Secondhand Smoke and Cancer Risk to Family Members

We take the biopsy specimen and extract the DNA from the cancer cell, then sequence it to identify where something has gone wrong in the DNA or RNA, which tells us why that individual developed the cancer. Through this we identify specific mutations that may be the probable reason. Research is ongoing to counteract every change found on NGS, but currently we have a few drugs available for certain specific mutations — if we find one of those, we give that specific drug and the patient benefits.

If you don't have a PET-CT, the second-best modality is a CT scan of the probable areas — chest, abdomen, and maybe head and neck depending on the cancer — which will give some answers on staging. As for treatment: chemotherapy is calculated as per the height, weight and profile of the patient, not given as a simple fixed dose. There are specific mixing criteria — it cannot be mixed like an antibiotic — and India has specific mixing units where care is taken over contamination and dosing. Drugs also have to be given over an appropriate infusion time, since infusing over the wrong duration causes more side effects. We also have monitoring systems running during chemotherapy to catch problems early, and targeted therapies and immunotherapies have specific temperature and light-sensitivity handling requirements that are important to follow correctly.

Previously it used to take 30 days, and it still does in most institutes, but with the advanced machines we now have, our turnaround time is only about five to six working days — even including a Sunday, a comprehensive NGS report is usually ready by about the seventh day.

The cost is very different for every cancer and every stage — it can vary from a few thousand rupees to a million rupees. The good news is that targeted therapy and immunotherapy drugs, which used to be very costly, now have more reasonable generic alternatives. For example, a drug that used to cost about $5,000 for a single dose as immunotherapy now costs just around $1,000 for a single dose. We also try to provide assistance programmes through indications approved by the companies that manufacture these drugs, to help patients financially.

It is not available for everyone blanketly — you first need to identify the target on the cell, which is where NGS and special staining come in. Not every individual harbours those targets, but many do, and we then use specific targeted drugs. Immunotherapy is not available for all cancers either, but with present indications it is available for the majority of advanced cancers — about 70% of advanced cancers would be candidates for some form of immunotherapy. There are specific criteria that must be met; giving it without meeting those criteria would not help the patient and would just be a financial waste.

A non-smoker's risk of lung cancer increases by around 30 percent when someone else smokes in the home.

Data going back to 2001 showed secondhand smoke was responsible for around 60,000 non-smoker deaths annually, a figure likely to have grown substantially since then.

Because their smoking directly raises the cancer risk of family members who share their living space, which is a compelling reason to quit even for those who feel indifferent to the risk to themselves.